Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 19/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776818 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3 | |
| SCHEMBL31622252 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3 | |
| SCHEMBL30180126 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3 | |
| SCHEMBL30169171 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3 | |
| SCHEMBL22526628 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3 | |
| SCHEMBL23832628 | 1.00 | CRBN (0.57) | CRBNDDB1IKZF3 | |
| SCHEMBL21997046 | 0.99 | CRBN (0.58) | CRBNDDB1IKZF3 | |
| SCHEMBL21069913 | 0.96 | CRBN (0.60) | CRBNDDB1IKZF3 | |
| SCHEMBL21997891 | 0.93 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL21997960 | 0.91 | CRBN (0.54) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CRBN 2559/4885DDB1 3488/4885IKZF3 1797/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CRBN 2559/4885DDB1 3488/4885IKZF3 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.